New clinical trial data: Multiple sclerosis drug candidate also shows promise for ulcerative colitis

Positive new clinical data have been released on a drug candidate for ulcerative colitis. In the study, 199 patients with active, moderate to severe disease, the drug candidate RPC1063 has potential to significantly improve the treatment paradigm for ulcerative colitis patients. The latest results show that, after eight weeks of treatment with a 1 mg dose of RPC1063, 16.4 percent of patents were in clinical remission, as compared to 6.2 percent of patients on placebo.

Read the whole article on Science Daily

More from Science Daily